AZN.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 02:09):

Stats
今日成交量	1.64M
平均成交量	2.94M
市值	186.80B
EPS	£0 ( 2024-04-24 )
下一个收益日期	( £1.530 ) 2024-06-04
Last Dividend	£71.80 ( 2023-08-10 )
Next Dividend	£0 ( N/A )
P/E	37.31
ATR14	£7.95 (0.07%)

音量相关性

長: 0.07 (neutral)

短: -0.06 (neutral)

Signal:(65.972) Neutral

AstraZeneca PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AstraZeneca PLC 相关性 - 货币/商品

-0.70
( moderate negative )

-0.65
( weak negative )

-0.84
( strong negative )

-0.70
( moderate negative )

0.84
( strong )

AstraZeneca PLC 财务报表

Annual	2023
营收:	£45.81B
毛利润:	£37.54B (81.95 %)
EPS:	£3.84

FY	2023
营收:	£45.81B
毛利润:	£37.54B (81.95 %)
EPS:	£3.84

FY	2022
营收:	£44.35B
毛利润:	£31.96B (72.06 %)
EPS:	£2.12

FY	2021
营收:	£37.42B
毛利润:	£24.98B (66.76 %)
EPS:	£0.0854

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£76.40 (N/A)	£0 (N/A)	£162.80 (N/A)	£0 (N/A)	£71.80 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

AstraZeneca PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.82 - Stable (3.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£10.50	1993-09-20
Last Dividend	£71.80	2023-08-10
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	61	--
Total Paid Out	£3 651.80	--
Avg. Dividend % Per Year	1.07%	--
Score	4.42	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.82
Div. Directional Score	7.92	--

Next Divdend (Est)
(2024-07-01)

£70.63 Estimate 7.48 %

Dividend Stability

0.30 Very Poor

Dividend Score

4.42

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	£10.50	1.75%
1994	£27.75	3.38%
1995	£29.00	3.38%
1996	£32.25	2.65%
1997	£36.00	2.24%
1998	£39.00	1.87%
1999	£42.20	1.65%
2000	£44.39	1.77%
2001	£47.56	1.41%
2002	£47.90	1.55%
2003	£43.95	1.98%
2004	£45.40	1.69%
2005	£56.20	2.98%
2006	£78.40	2.73%
2007	£88.30	3.18%
2008	£95.50	4.45%
2009	£140.80	5.04%
2010	£150.30	5.11%
2011	£168.60	5.64%
2012	£181.70	5.96%
2013	£179.70	6.05%
2014	£169.90	4.78%
2015	£182.50	3.98%
2016	£199.70	4.46%
2017	£219.10	4.94%
2018	£202.00	3.96%
2019	£218.70	3.70%
2020	£216.00	2.82%
2021	£202.20	2.72%
2022	£221.70	2.62%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TON.L	Dividend Knight	2023-06-01	Annually	32	1.80%
LTHM.L	Dividend Knight	2023-08-03	Semi-Annually	33	0.87%
COA.L	Dividend Knight	2023-10-19	Annually	33	1.79%
ROR.L	Dividend King	2023-08-17	Semi-Annually	32	1.43%
HHI.L	Dividend King	2023-09-14	Quarterly	25	3.58%
AUTO.L	Dividend Knight	2023-08-24	Annually	9	0.79%
VLX.L	Dividend Knight	2023-07-20	Sporadic	32	0.82%
MRCH.L	Dividend King	2023-07-06	Quarterly	53	3.07%
DIVI.L	Dividend Knight	2023-09-28	Quarterly	14	1.99%
SHOE.L	Dividend Knight	2023-07-13	Annually	10	2.57%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.133	1.500	7.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0619	1.200	7.94	9.52	[0 - 0.3]
returnOnEquityTTM	0.168	1.500	9.25	10.00	[0.1 - 1]
payoutRatioTTM	0.706	-1.000	2.94	-2.94	[0 - 1]
currentRatioTTM	0.886	0.800	-0.572	-0.458	[1 - 3]
quickRatioTTM	0.661	0.800	-0.820	-0.656	[0.8 - 2.5]
cashRatioTTM	0.271	1.500	9.60	10.00	[0.2 - 2]
debtRatioTTM	0.338	-1.500	4.37	-6.56	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.73	2.00	8.13	10.00	[0 - 20]
debtEquityRatioTTM	0.923	-1.500	6.31	-9.46	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.465	0.800	-0.230	-0.184	[0.5 - 2]
Total Score				11.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.99	1.000	6.36	0	[1 - 100]
returnOnEquityTTM	0.168	2.50	9.52	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.73	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	1.189	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
payoutRatioTTM	0.706	1.500	2.94	-2.94	[0 - 1]
pegRatioTTM	-56.74	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.204	1.000	7.41	0	[0.1 - 0.5]
Total Score				4.82

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.